2011 Scrip 100: Experimental collaboration model to drive Merck cancer research
This article was originally published in Scrip
In May 2010, Merck & Co launched an oncology collaborative trials network (Onconet) with leading international cancer research centres to speed up the development of its drug and vaccine candidates. The global research sites will lead the design and conduct of Phase 0 to Phase IIa clinical studies of Merck's investigational oncology candidates. Merck says that every year, the network will enrol approximately 1,200 patients in 30 to 40 clinical trials.
You may also be interested in...
Nano-X Imaging is on a mission to disrupt the market for X-ray imaging equipment by offering a low-cost medical imaging service to untapped markets through a network of equipment dotted around the world. However, some shareholders are claiming the company mislead investors.
The test measures the relative level of antibodies, which could aid vaccine rollout.
The market for devices to treat chronic obstructive pulmonary disease (COPD) is set to grow by 5.0% annually in the next three years, with the US market expanding by 5.7% per year, according to the Meddevicetracker Dashboard.